Search

Publications

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.

SWG Educational Activities

EHA2023 Hybrid CongressDate and locationJune 8–11, 2023, in Frankfurt, Germany. ChairMarie Jose Kersten

Case discussions
Follicular Lymphoma: Martin Dreylng, Daphne De Jong. Double hit Lymphoma: Andrew Davies, Elias Campo. T-follicular helper cell lymphoma: Andrew Davies, Daphne De Jong.

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Jun 11 2016 Posted in Press releases

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Jun 10 2016 Posted in Press releases

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Meeting program

Thursday, October 12*All times are in EET.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.